Antibody Production Market

Global Antibody Production Market Size (2023 to 2028)

The size of the global antibody production market was worth USD 11.35 billion in 2022 and this market is projected to be growing at a CAGR of 14.44% from 2023 to 2028 and worth USD 25.49 billion by 2027 from USD 12.98 billion in 2023.

An antibody, also known as immunoglobulin, is a Y-shaped protein that the immune system produces to protect the body against foreign invaders. When an infection is detected, the immune system produces antibodies in vivo; however, antibodies can also be produced in vitro. The antibody production covers commodities utilized in antibody bioprocessing's upstream, downstream, and filtering stages. Antibody manufacturing is an important aspect of biotechnology and drug development operations in research and development departments. Antibodies are used to treat a wide range of disorders, such as cancer, rheumatoid arthritis, and other serious diseases. Antibodies are host proteins produced by the immune system in reaction to foreign molecules entering the body. The immune system detects the presence of foreign molecules known as antigens and begins the manufacture of antibodies capable of binding to the antigens. B-lymphocytes produce antibodies, which circulate throughout the blood and lymph, binding to their specific antigen and allowing it to be removed from circulation.

Impact of COVID-19 on the global antibody production market:

The COVID-19 pandemic is an unprecedented worldwide public health threat that is expected to have a beneficial influence on the monoclonal antibody market for the development of COVID-19 monoclonal antibody therapy. The rapid production of a significant number of SARS-CoV-2 neutralizing monoclonal antibodies has been aided by the understanding of the urgent need for treatments available on a worldwide scale. Consequently, COVID-19 infection is predicted to boost growth and opportunities for monoclonal antibody major players during the forecast period. Antibodies against SARS-CoV-2 are critical for outsmarting the virus, as a proper neutralizing response would significantly reduce the number of virions capable of infecting ACE-2 receptor-expressing cells. As a result, the scientific community reacting to the pandemic must prioritize research on antibody responses to SARS-CoV-2, both in terms of prophylactic and treatment.

Antibody response to this virus, on the other hand, is still a source of debate and must be carefully addressed. Many issues of contention surrounding antibody responses to SARS-CoV-2 include vaccine effectiveness studies, the likelihood of antibody-dependent enhancement, and convalescent plasma therapy, and lots more research remains to be done in some of these disciplines. In the longitudinal representation of antibody titers against Spike-RBD-E484Q, the antibody response following the first COVID-19 vaccination dose for all totally vaccinated patients, whether infused with bamlanivimab or a placebo, is represented. By considering all these factors market has had positive growth during this pandemic.

MARKET DRIVERS:

Regulatory authorities' better approval rate of therapeutic antibodies, patent expiration of monoclonal antibodies, increased use of targeted immunotherapy, and more R&D spending by pharmaceutical and biotechnology companies are majorly accelerating the growth of the global antibody production market.

Antibodies are used to treat a range of diseases, including cancer, rheumatoid arthritis, and other chronic conditions. Because of its sensitivity to cancer cells, while avoiding damage to non-target cells, targeted therapy is gaining popularity. Large pharmaceutical corporations have also shifted their focus to biopharma due to biologics' high success rates and revenues. All these factors are driving the market to positive growth.

Infectious disease frequency is predicted to rise, as is the demand for protein therapies, providing growth opportunities for participants in this market. Furthermore, the market is further expanding as the prevalence of infectious diseases rises, as does the demand for protein therapeutics. In the near future, the increase in the number of significant players investing in advanced technologies and partnering with other key players is expected to have a beneficial impact on market potential. Abcellera, for example, uses cutting-edge technology to analyze antibodies derived from single B cells, map and evaluate natural immune responses, and develop new antibody therapeutics.

MARKET RESTRAINTS:

However, the growth of the global antibody production market is projected to be hampered by the high costs of antibody manufacture and strict regulatory regulations. During the forecast period, a limited number of commercially available antibody medicines are likely to challenge overall market growth.

REPORT COVERAGE:

This research report on the global antibody production market has been segmented and sub-segmented based on type, end-user, and region.

Antibody Production Market – By Type:

• Polyclonal antibody
• Monoclonal antibody
• Murine
• Chimeric
• Humanized

Based on type, the monoclonal antibodies segment accounted for the largest share of the global antibody production market in 2020. Not just for infectious diseases produced by bacteria, viruses, and protozoa, but also for cancer, metabolic, and hormonal problems, monoclonal antibodies offer a wide range of applications in diagnostics, treatments, and targeted drug delivery systems. Due to increased investment in monoclonal antibody research and growth in antibody-based product releases, this segment is likely to hold the largest market share during the forecast period.

Antibody Production Market – By End-User:

• Pharmaceutical and biotechnology companies
• Research laboratories
• Others

Based on the end-user, the pharmaceutical and biotechnology companies segment dominated the global antibody production market, accounting for the majority of the revenue in 2020. Corporations are making large investments in research and development operations to satisfy industry restrictions, which is a key market driver for this end-user segment.

Antibody Production Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Geographically, the North American antibody production market is observed to have the most considerable share of the global antibody production market and is predicted to maintain this trend during the forecast period, with minor fluctuations. The presence of advantageous healthcare infrastructure, as well as the increased prevalence of numerous chronic diseases, are the primary drivers of market expansion in this region. Furthermore, the approval of monoclonal antibodies for the treatment of cancer and other disorders is on the rise, which is one of the primary factors driving the market's rapid expansion in North America.

Japan is the largest market for custom antibodies in the Asia Pacific. The presence of key market players and their involvement in product development are key driving factors in Japan's market growth, as is the high demand for research, growing government support, constantly-changing disease profiles, and increasing funding activities, which are predicted to be boosting biotechnology's performance.

Due to the existence of multiple renowned pharmaceutical and biotechnology businesses, Europe is predicted to come in second due to significant demand for antibody-drug conjugates for therapeutic and diagnostic uses.

KEY MARKET PARTICIPANTS:

GeneTex, Inc., Thermo Fisher Scientific, Inc., Eli Lilly and Company, Merck KGaA, Pall Corporation, Sigma-Aldrich Corporation, Eppendorf AG, Cellab GmbH, Abcam PLC, and FiberCell Systems Inc. are some of the dominating companies operating in the global antibody production market profiled in this report.

RECENT HAPPENINGS IN THIS MARKET:

• FairJourney Biologics and IONTAS launched Flow Eighteen38, a protein sciences branch, in February 2021. The new division focuses on the purification and characterization needs of a diverse spectrum of customers, including research institutes and start-ups, as well as for biotechnology and biopharmaceutical companies.
• AmMag SA, a new purification system from GenScript, was launched in January 2019. This technology speeds up the purification of proteins and antibodies by simplifying the procedure.